Sidmap Provides Metabolic Phenotyping Services
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Sidmap has announced the signing of agreements with investigators and researchers at Harvard Medical School's Joslin Diabetes Center and the University of Utah to use its isotope-based metabolic phenotyping services.
Mary-Elizabeth Patti, M.D., of the Joslin Diabetes Center at Harvard Medical School, engaged Sidmap to conduct a series of profiles to determine the metabolic perturbations of a diabetes model currently under investigation.
"The early information provided by Sidmap has been extremely revealing. The results were provided promptly and I expect to continue working with Dr. Boros and his team in the future," Dr. Patti said.
Don McClain, Ph.D., of the University of Utah, is using Sidmap's metabolic phenotyping services to evaluate an in vivo model for type II diabetes.
"The work Drs. Boros and Lee are doing is extremely exciting and we are expecting some unique insights from the metabolic profiles Sidmap is providing," said Dr. McClain.
"We are extremely pleased that these prestigious academic institutions have chosen SIDMAP as their metabolic solutions provider," said David Manheim, Sidmap's Vice President of Operations and General Counsel.
He adds, "We continue to work with pharmaceutical and biotech companies as well as academic institutions which have embraced our technology as a useful tool to enhance their research and drug development efforts. Our pipeline is robust and should continue to grow as more people learn about the dynamic biochemical information we provide."
Mary-Elizabeth Patti, M.D., of the Joslin Diabetes Center at Harvard Medical School, engaged Sidmap to conduct a series of profiles to determine the metabolic perturbations of a diabetes model currently under investigation.
"The early information provided by Sidmap has been extremely revealing. The results were provided promptly and I expect to continue working with Dr. Boros and his team in the future," Dr. Patti said.
Don McClain, Ph.D., of the University of Utah, is using Sidmap's metabolic phenotyping services to evaluate an in vivo model for type II diabetes.
"The work Drs. Boros and Lee are doing is extremely exciting and we are expecting some unique insights from the metabolic profiles Sidmap is providing," said Dr. McClain.
"We are extremely pleased that these prestigious academic institutions have chosen SIDMAP as their metabolic solutions provider," said David Manheim, Sidmap's Vice President of Operations and General Counsel.
He adds, "We continue to work with pharmaceutical and biotech companies as well as academic institutions which have embraced our technology as a useful tool to enhance their research and drug development efforts. Our pipeline is robust and should continue to grow as more people learn about the dynamic biochemical information we provide."
